Stockreport

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF Results showed significant improvement in red blood cell transfusion independence compared to placebo Safety profile generally consistent with pr [Read more]